人多能干细胞（hPSC）心肌细胞分化试剂盒，50 mL

Human pluripotent stem cells (hPSC), including embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC), possess the capability of differentiating into all derivatives of the three germ layers. Given that adult cardiomyocytes do not typically proliferate, hPSC can potentially provide an unlimited supply of cardiomyocytes. The cardiomyocyte derived from hPSC can be used for drug screening, toxicity testing, and developmental studies.

The spontaneous cardiac differentiation of hPSC is inefficient, with less than 1% of cardiomyocytes present in the culture. The differentiation process can be significantly enhanced by adding growth factors (BMP4, activin A, and FGF2 etc.), and small molecules, or using mouse END-2 cell-conditioned medium. The appropriate temporal addition of growth factors is also critic for cardiac differentiation. The Wnt signaling pathway is one of the key regulators in cardiac differentiation of hPSC. Modulating the Wnt signaling activity at different stages of differentiation is sufficient to drive hPSC to differentiate into cardiomyocytes.

ScienCell’s Human Pluripotent Stem Cell Cardiomyocyte Differentiation Kit (PSCCDK) is specially designed to differentiate hPSC to cardiomyocytes at a high efficiency, combining growth factor induction with the temporal modulation of canonical Wnt signaling by small molecules. The kit efficiently converts monolayer-cultured pluripotent stem cells to contracting cardiomyocytes within 15 days under serum-free and feeder-free conditions. With the PSCCDK there is no need for the intermediate embryoid body formation. The kit contains 3 differentiation media, 1 basal medium, and 1 growth supplement. One kit is enough to differentiate 2 12-well plates of cells.

The PSCCDK kit is developed using hESC WA09 (H9) cultured in STEMium® medium (Cat. #5801). We consistently get a sheet of cardiomyocytes from H9 cells. Using the kit, we are also able to derive contracting clusters from a hiPSC line which is generated from human dermal fibroblasts using mRNA reprogramming technology. The hPSC-derived cardiomyocyte cells can be passaged and further enriched using our Cardiomyocyte Selective Medium (Cat. #5911).

人多能干细胞（hPSC），包括胚胎干细胞（ESC）和诱导多能干细胞（iPSC），具有分化为三大胚层所有衍生细胞类型的潜能。由于成体心肌细胞通常不具备增殖能力，hPSC 有望为心肌细胞提供几乎无限的来源。由 hPSC 分化获得的心肌细胞可广泛应用于药物筛选、毒性检测及发育研究等领域。

hPSC 的自发性心脏分化效率较低，培养体系中通常仅有不足1%的细胞为心肌细胞。通过添加生长因子（如 BMP4、Activin A 和 FGF2 等）、小分子化合物，或使用小鼠 END-2 细胞条件培养基，可显著提高分化效率。此外，生长因子的时序性添加对心肌分化至关重要。Wnt 信号通路是调控 hPSC 心肌分化的关键通路之一，在分化不同阶段对其进行动态调控即可有效诱导 hPSC 分化为心肌细胞。

ScienCell 人多能干细胞心肌细胞分化试剂盒（PSCCDK）通过结合生长因子诱导与小分子对经典 Wnt 信号通路的时序调控，实现 hPSC 向心肌细胞的高效分化。在无血清、无饲养层条件下，该试剂盒可在15天内将单层培养的多能干细胞高效转化为具有收缩功能的心肌细胞。使用该试剂盒无需经过胚状体（embryoid body）形成阶段。试剂盒包含3种分化培养基、1种基础培养基以及1种生长补充剂，一套试剂盒可用于完成2个12孔板细胞的分化实验。

PSCCDK 试剂盒基于在 STEMium® 培养基（产品编号：5801）中培养的人胚胎干细胞系 WA09（H9）开发而成，在该体系下可稳定获得成片的心肌细胞。此外，使用该试剂盒还可从来源于人真皮成纤维细胞、经 mRNA 重编程获得的 hiPSC 细胞系中诱导形成具有收缩功能的细胞团。分化获得的 hPSC 来源心肌细胞可通过传代培养，并结合心肌细胞选择性培养基（Cardiomyocyte Selective Medium，产品编号：5911）进一步富集。